-
1
-
-
84924271853
-
Global cancer statistics, 2012
-
PMID: 25651787
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]
-
(2015)
CA Cancer J Clin
, vol.65
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
Ferlay, J.4
Lortet-Tieulent, J.5
Jemal, A.6
-
2
-
-
84867122727
-
ESMO Consensus Guidelines for management of patients with colon and rectal cancer
-
PMID: 23012255
-
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516 [PMID: 23012255 DOI: 10.1093/annonc/mds236]
-
(2012)
A Personalized Approach to Clinical Decision Making. Ann Oncol
, vol.23
, pp. 2479-2516
-
-
Schmoll, H.J.1
Van Cutsem, E.2
Stein, A.3
Valentini, V.4
Glimelius, B.5
Haustermans, K.6
Nordlinger, B.7
Van De Velde, C.J.8
Balmana, J.9
Regula, J.10
Nagtegaal, I.D.11
Beets-Tan, R.G.12
Arnold, D.13
Ciardiello, F.14
Hoff, P.15
Kerr, D.16
Köhne, C.H.17
Labianca, R.18
Price, T.19
Scheithauer, W.20
Sobrero, A.21
Tabernero, J.22
Aderka, D.23
Barroso, S.24
Bodoky, G.25
Douillard, J.Y.26
El Ghazaly, H.27
Gallardo, J.28
Garin, A.29
Glynne-Jones, R.30
Jordan, K.31
Meshcheryakov, A.32
Papamichail, D.33
Pfeiffer, P.34
Souglakos, I.35
Turhal, S.36
Cervantes, A.37
more..
-
3
-
-
84911474269
-
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
PMID: 25190710
-
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii1-iii9 [PMID: 25190710 DOI: 10.1093/annonc/mdu260]
-
(2014)
Ann Oncol
, vol.25
, pp. iii1-iii9
-
-
Van Cutsem, E.1
Cervantes, A.2
Nordlinger, B.3
Arnold, D.4
-
4
-
-
84929310633
-
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
-
PMID: 25970050
-
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919 [PMID: 25970050 DOI: 10.1056/NEJMoa1414325]
-
(2015)
N Engl J Med
, vol.372
, pp. 1909-1919
-
-
Mayer, R.J.1
Van Cutsem, E.2
Falcone, A.3
Yoshino, T.4
Garcia-Carbonero, R.5
Mizunuma, N.6
Yamazaki, K.7
Shimada, Y.8
Tabernero, J.9
Komatsu, Y.10
Sobrero, A.11
Boucher, E.12
Peeters, M.13
Tran, B.14
Lenz, H.J.15
Zaniboni, A.16
Hochster, H.17
Cleary, J.M.18
Prenen, H.19
Benedetti, F.20
Mizuguchi, H.21
Makris, L.22
Ito, M.23
Ohtsu, A.24
more..
-
5
-
-
0035256698
-
Untangling the ERBB signalling network
-
PMID: 11252954
-
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137 [PMID: 11252954 DOI: 10.1038/35052073]
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, pp. 127-137
-
-
Yarden, Y.1
Sliwkowski, M.X.2
-
6
-
-
18344390418
-
ERBB receptors and cancer: The complexity of targeted inhibitors
-
PMID: 15864276
-
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 [PMID: 15864276 DOI: 10.1038/nrc1609]
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 341-354
-
-
Hynes, N.E.1
Lane, H.A.2
-
7
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
PMID: 18337605
-
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]
-
(2008)
N Engl J Med
, vol.358
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
8
-
-
69949127786
-
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
-
PMID: 19737224
-
Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1-9 [PMID: 19737224 DOI: 10.1111/j.1365-2249.2009.03992.x]
-
(2009)
Clin Exp Immunol
, vol.158
, pp. 1-9
-
-
Martinelli, E.1
De Palma, R.2
Orditura, M.3
De Vita, F.4
Ciardiello, F.5
-
9
-
-
84899981129
-
Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study
-
PMID: 24739896
-
Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15: 569-579 [PMID: 24739896 DOI: 10.1016/S1470-2045(14)70118-4]
-
(2014)
Lancet Oncol
, vol.15
, pp. 569-579
-
-
Price, T.J.1
Peeters, M.2
Kim, T.W.3
Li, J.4
Cascinu, S.5
Ruff, P.6
Suresh, A.S.7
Thomas, A.8
Tjulandin, S.9
Zhang, K.10
Murugappan, S.11
Sidhu, R.12
-
10
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
PMID: 15269313
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
11
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
PMID: 17470858
-
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
-
(2007)
J Clin Oncol
, vol.25
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.L.7
Van Laethem, J.L.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.G.12
-
12
-
-
84908431348
-
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
-
PMID: 25293556
-
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4: 1269-1280 [PMID: 25293556 DOI: 10.1158/2159-8290. CD-14-0462]
-
(2014)
Cancer Discov
, vol.4
, pp. 1269-1280
-
-
Misale, S.1
Nicolantonio, F.D.I.2
Sartore-Bianchi, A.3
Siena, S.4
Bardelli, A.5
-
13
-
-
84914112343
-
Tumour heterogeneity and the evolution of polyclonal drug resistance
-
PMID: 25087573
-
Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8: 1095-1111 [PMID: 25087573 DOI: 10.1016/j.molonc.2014.06.005]
-
(2014)
Mol Oncol
, vol.8
, pp. 1095-1111
-
-
Burrell, R.A.1
Swanton, C.2
-
14
-
-
84884365015
-
The causes and consequences of genetic heterogeneity in cancer evolution
-
PMID: 24048066
-
Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345 [PMID: 24048066 DOI: 10.1038/nature12625]
-
(2013)
Nature
, vol.501
, pp. 338-345
-
-
Burrell, R.A.1
McGranahan, N.2
Bartek, J.3
Swanton, C.4
-
15
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
PMID: 15677699
-
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810 [PMID: 15677699 DOI: 10.1200/JCO.2005.08.037]
-
(2005)
J Clin Oncol
, vol.23
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
Shah, M.4
Schwartz, G.K.5
Tse, A.6
Hamilton, A.7
Pan, D.8
Schrag, D.9
Schwartz, L.10
Klimstra, D.S.11
Fridman, D.12
Kelsen, D.P.13
Saltz, L.B.14
-
16
-
-
84929141867
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials
-
PMID: 25115304
-
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21 [PMID: 25115304 DOI: 10.1093/annonc/mdu378]
-
(2015)
Ann Oncol
, vol.26
, pp. 13-21
-
-
Sorich, M.J.1
Wiese, M.D.2
Rowland, A.3
Kichenadasse, G.4
McKinnon, R.A.5
Karapetis, C.S.6
-
17
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
PMID: 20619739
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762 [PMID: 20619739 DOI: 10.1016/S1470-2045(10)70130-3]
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
Kalogeras, K.T.7
Kotoula, V.8
Papamichael, D.9
Laurent-Puig, P.10
Penault-Llorca, F.11
Rougier, P.12
Vincenzi, B.13
Santini, D.14
Tonini, G.15
Cappuzzo, F.16
Frattini, M.17
Molinari, F.18
Saletti, P.19
De Dosso, S.20
Martini, M.21
Bardelli, A.22
Siena, S.23
Sartore-Bianchi, A.24
Tabernero, J.25
Macarulla, T.26
Fiore, F.D.I.27
Gangloff, A.O.28
Ciardiello, F.29
Pfeiffer, P.30
Qvortrup, C.31
Hansen, T.P.32
Van Cutsem, E.33
Piessevaux, H.34
Lambrechts, D.35
Delorenzi, M.36
Tejpar, S.37
more..
-
18
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
PMID: 23729478
-
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658-673 [PMID: 23729478 DOI: 10.1158/2159-8290.CD-12-0558]
-
(2013)
Cancer Discov
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
Hobor, S.4
Valtorta, E.5
Siravegna, G.6
Sartore-Bianchi, A.7
Scala, E.8
Cassingena, A.9
Zecchin, D.10
Apicella, M.11
Migliardi, G.12
Galimi, F.13
Lauricella, C.14
Zanon, C.15
Perera, T.16
Veronese, S.17
Corti, G.18
Amatu, A.19
Gambacorta, M.20
Diaz, L.A.21
Sausen, M.22
Velculescu, V.E.23
Comoglio, P.24
Trusolino, L.25
Nicolantonio, F.D.I.26
Giordano, S.27
Siena, S.28
more..
-
19
-
-
84862772839
-
A molecularly annotated platform of patient-derived xenografts (xenopatients) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
-
PMID: 22586653
-
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts (xenopatients) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1: 508-523 [PMID: 22586653 DOI: 10.1158/2159-8290.CD-11-0109]
-
(2011)
Cancer Discov
, vol.1
, pp. 508-523
-
-
Bertotti, A.1
Migliardi, G.2
Galimi, F.3
Sassi, F.4
Torti, D.5
Isella, C.6
Corà, D.7
Nicolantonio, F.D.I.8
Buscarino, M.9
Petti, C.10
Ribero, D.11
Russolillo, N.12
Muratore, A.13
Massucco, P.14
Pisacane, A.15
Molinaro, L.16
Valtorta, E.17
Sartore-Bianchi, A.18
Risio, M.19
Capussotti, L.20
Gambacorta, M.21
Siena, S.22
Medico, E.23
Sapino, A.24
Marsoni, S.25
Comoglio, P.M.26
Bardelli, A.27
Trusolino, L.28
more..
-
20
-
-
84856717005
-
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
-
PMID: 22270724
-
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18: 221-223 [PMID: 22270724 DOI: 10.1038/nm.2609]
-
(2012)
Nat Med
, vol.18
, pp. 221-223
-
-
Montagut, C.1
Dalmases, A.2
Bellosillo, B.3
Crespo, M.4
Pairet, S.5
Iglesias, M.6
Salido, M.7
Gallen, M.8
Marsters, S.9
Tsai, S.P.10
Minoche, A.11
Seshagiri, S.12
Serrano, S.13
Himmelbauer, H.14
Bellmunt, J.15
Rovira, A.16
Settleman, J.17
Bosch, F.18
Albanell, J.19
-
21
-
-
84932606172
-
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
-
PMID: 25623215
-
Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res 2015; 21: 2157-2166 [PMID: 25623215]
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2157-2166
-
-
Arena, S.1
Bellosillo, B.2
Siravegna, G.3
Martínez, A.4
Cañadas, I.5
Lazzari, L.6
Ferruz, N.7
Russo, M.8
Misale, S.9
González, I.10
Iglesias, M.11
Gavilan, E.12
Corti, G.13
Hobor, S.14
Crisafulli, G.15
Salido, M.16
Sánchez, J.17
Dalmases, A.18
Bellmunt, J.19
De Fabritiis, G.20
Rovira, A.21
Nicolantonio, F.D.I.22
Albanell, J.23
Bardelli, A.24
Montagut, C.25
more..
-
22
-
-
84896371874
-
Detection of circulating tumor DNA in early-and late-stage human malignancies
-
PMID: 24553385
-
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24 [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094]
-
(2014)
Sci Transl Med
, vol.6
, pp. 224ra24
-
-
Bettegowda, C.1
Sausen, M.2
Leary, R.J.3
Kinde, I.4
Wang, Y.5
Agrawal, N.6
Bartlett, B.R.7
Wang, H.8
Luber, B.9
Alani, R.M.10
Antonarakis, E.S.11
Azad, N.S.12
Bardelli, A.13
Brem, H.14
Cameron, J.L.15
Lee, C.C.16
Fecher, L.A.17
Gallia, G.L.18
Gibbs, P.19
Le, D.20
Giuntoli, R.L.21
Goggins, M.22
Hogarty, M.D.23
Holdhoff, M.24
Hong, S.M.25
Jiao, Y.26
Juhl, H.H.27
Kim, J.J.28
Siravegna, G.29
Laheru, D.A.30
Lauricella, C.31
Lim, M.32
Lipson, E.J.33
Marie, S.K.34
Netto, G.J.35
Oliner, K.S.36
Olivi, A.37
Olsson, L.38
Riggins, G.J.39
Sartore-Bianchi, A.40
Schmidt, K.41
Shih, L.M.42
Oba-Shinjo, S.M.43
Siena, S.44
Theodorescu, D.45
Tie, J.46
Harkins, T.T.47
Veronese, S.48
Wang, T.L.49
Weingart, J.D.50
Wolfgang, C.L.51
Wood, L.D.52
Xing, D.53
Hruban, R.H.54
Wu, J.55
Allen, P.J.56
Schmidt, C.M.57
Choti, M.A.58
Velculescu, V.E.59
Kinzler, K.W.60
Vogelstein, B.61
Papadopoulos, N.62
Diaz, L.A.63
more..
-
23
-
-
0024376173
-
Ras oncogenes in human cancer: A review
-
PMID: 2547513
-
Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689 [PMID: 2547513]
-
(1989)
Cancer Res
, vol.49
, pp. 4682-4689
-
-
Bos, J.L.1
-
24
-
-
58749102224
-
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
-
PMID: 19056857
-
Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13: 1270-1275 [PMID: 19056857 DOI: 10.1634/theoncologist.2008-0181]
-
(2008)
Oncologist
, vol.13
, pp. 1270-1275
-
-
Santini, D.1
Loupakis, F.2
Vincenzi, B.3
Floriani, I.4
Stasi, I.5
Canestrari, E.6
Rulli, E.7
Maltese, P.E.8
Andreoni, F.9
Masi, G.10
Graziano, F.11
Baldi, G.G.12
Salvatore, L.13
Russo, A.14
Perrone, G.15
Tommasino, M.R.16
Magnani, M.17
Falcone, A.18
Tonini, G.19
Ruzzo, A.20
more..
-
25
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
PMID: 16618717
-
Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995 [PMID: 16618717 DOI: 10.1158/0008-5472. CAN-06-0191]
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Lièvre, A.1
Bachet, J.B.2
Le Corre, D.3
Boige, V.4
Landi, B.5
Emile, J.F.6
Côté, J.F.7
Tomasic, G.8
Penna, C.9
Ducreux, M.10
Rougier, P.11
Penault-Llorca, F.12
Laurent-Puig, P.13
-
26
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
PMID: 18946061
-
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
O'Callaghan, C.J.4
Tu, D.5
Tebbutt, N.C.6
Simes, R.J.7
Chalchal, H.8
Shapiro, J.D.9
Robitaille, S.10
Price, T.J.11
Shepherd, L.12
Au, H.J.13
Langer, C.14
Moore, M.J.15
Zalcberg, J.R.16
-
27
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
PMID: 18316791
-
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
Juan, T.7
Sikorski, R.8
Suggs, S.9
Radinsky, R.10
Patterson, S.D.11
Chang, D.D.12
-
28
-
-
84979537937
-
-
European Medicines Agency. Committee for Medicinal Products for Human Use. May 2008 Plenary Meeting Monthly Report
-
European Medicines Agency. Committee for Medicinal Products for Human Use. May 2008 Plenary Meeting Monthly Report. Available from: URL: http://www.emea.europa.eu/pdfs/human/press/pr/27923508en.pdf
-
-
-
-
29
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
PMID: 20921465
-
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, B?asi?ska-Morawiec M, Ŝmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
Humblet, Y.7
Bodoky, G.8
Cunningham, D.9
Jassem, J.10
Rivera, F.11
Kocákova, I.12
Ruff, P.13
Basiska-Morawiec, M.14
Ŝmakal, M.15
Canon, J.L.16
Rother, M.17
Oliner, K.S.18
Wolf, M.19
Gansert, J.20
more..
-
30
-
-
78149239651
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
PMID: 20921462
-
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055]
-
(2010)
J Clin Oncol
, vol.28
, pp. 4706-4713
-
-
Peeters, M.1
Price, T.J.2
Cervantes, A.3
Sobrero, A.F.4
Ducreux, M.5
Hotko, Y.6
André, T.7
Chan, E.8
Lordick, F.9
Punt, C.J.10
Strickland, A.H.11
Wilson, G.12
Ciuleanu, T.E.13
Roman, L.14
Van Cutsem, E.15
Tzekova, V.16
Collins, S.17
Oliner, K.S.18
Rong, A.19
Gansert, J.20
more..
-
31
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
PMID: 21502544
-
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
Folprecht, G.4
Nowacki, M.P.5
Cascinu, S.6
Shchepotin, I.7
Maurel, J.8
Cunningham, D.9
Tejpar, S.10
Schlichting, M.11
Zubel, A.12
Celik, I.13
Rougier, P.14
Ciardiello, F.15
-
32
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
PMID: 24024839
-
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, B?asi?ska-Morawiec M, Ŝmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
Humblet, Y.7
Bodoky, G.8
Cunningham, D.9
Jassem, J.10
Rivera, F.11
Kocákova, I.12
Ruff, P.13
Basiska-Morawiec, M.14
Ŝmakal, M.15
Canon, J.L.16
Rother, M.17
Williams, R.18
Rong, A.19
Wiezorek, J.20
Sidhu, R.21
Patterson, S.D.22
more..
-
33
-
-
84905870196
-
PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
-
PMID: 24687833
-
Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247 [PMID: 24687833 DOI: 10.1200/JCO.2013.53.2473]
-
(2014)
J Clin Oncol
, vol.32
, pp. 2240-2247
-
-
Schwartzberg, L.S.1
Rivera, F.2
Karthaus, M.3
Fasola, G.4
Canon, J.L.5
Hecht, J.R.6
Yu, H.7
Oliner, K.S.8
Go, W.Y.9
-
34
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
-
PMID: 25088940
-
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
Von Weikersthal, L.F.2
Decker, T.3
Kiani, A.4
Vehling-Kaiser, U.5
Al-Batran, S.E.6
Heintges, T.7
Lerchenmüller, C.8
Kahl, C.9
Seipelt, G.10
Kullmann, F.11
Stauch, M.12
Scheithauer, W.13
Hielscher, J.14
Scholz, M.15
Müller, S.16
Link, H.17
Niederle, N.18
Rost, A.19
Höffkes, H.G.20
Moehler, M.21
Lindig, R.U.22
Modest, D.P.23
Rossius, L.24
Kirchner, T.25
Jung, A.26
Stintzing, S.27
more..
-
35
-
-
84925324704
-
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
-
PMID: 25605843
-
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700 [PMID: 25605843 DOI: 10.1200/JCO.2014.59.4812]
-
(2015)
J Clin Oncol
, vol.33
, pp. 692-700
-
-
Van Cutsem, E.1
Lenz, H.J.2
Köhne, C.H.3
Heinemann, V.4
Tejpar, S.5
Melezínek, I.6
Beier, F.7
Stroh, C.8
Rougier, P.9
Van Krieken, J.H.10
Ciardiello, F.11
-
36
-
-
84930047088
-
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
-
PMID: 25937522
-
Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015; 51: 1243-1252 [PMID: 25937522 DOI: 10.1016/j.ejca.2015.04.007]
-
(2015)
Eur J Cancer
, vol.51
, pp. 1243-1252
-
-
Bokemeyer, C.1
Köhne, C.H.2
Ciardiello, F.3
Lenz, H.J.4
Heinemann, V.5
Klinkhardt, U.6
Beier, F.7
Duecker, K.8
Van Krieken, J.H.9
Tejpar, S.10
-
37
-
-
84906846009
-
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial
-
PMID: 24942275
-
Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014; 25: 1756-1761 [PMID: 24942275 DOI: 10.1093/annonc/mdu230]
-
(2014)
Ann Oncol
, vol.25
, pp. 1756-1761
-
-
Ciardiello, F.1
Normanno, N.2
Maiello, E.3
Martinelli, E.4
Troiani, T.5
Pisconti, S.6
Giuliani, F.7
Barone, C.8
Cartenì, G.9
Rachiglio, A.M.10
Montesarchio, V.11
Tonini, G.12
Rizzi, D.13
Cinieri, S.14
Bordonaro, R.15
Febbraro, A.16
De Vita, F.17
Orditura, M.18
Fenizia, F.19
Lambiase, M.20
Rinaldi, A.21
Tatangelo, F.22
Botti, G.23
Colucci, G.24
more..
-
38
-
-
84979540105
-
-
European Medicines Agency. Committee for Medicinal Products for Human Use. Available from
-
European Medicines Agency. Committee for Medicinal Products for Human Use. Available from: URL: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000558/WC500160158.pdf
-
-
-
-
39
-
-
84979540107
-
-
European Medicines Agency. Committee for Medicinal Products for Human Use
-
European Medicines Agency. Committee for Medicinal Products for Human Use. Available from: URL http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000741/WC500148667.pdf
-
-
-
-
40
-
-
84863000299
-
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
-
PMID: 22722843
-
Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540 [PMID: 22722843 DOI: 10.1038/nature11219]
-
(2012)
Nature
, vol.486
, pp. 537-540
-
-
Diaz, L.A.1
Williams, R.T.2
Wu, J.3
Kinde, I.4
Hecht, J.R.5
Berlin, J.6
Allen, B.7
Bozic, I.8
Reiter, J.G.9
Nowak, M.A.10
Kinzler, K.W.11
Oliner, K.S.12
Vogelstein, B.13
-
41
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
PMID: 22722830
-
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536 [PMID: 22722830 DOI: 10.1038/nature11156]
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
Yaeger, R.2
Hobor, S.3
Scala, E.4
Janakiraman, M.5
Liska, D.6
Valtorta, E.7
Schiavo, R.8
Buscarino, M.9
Siravegna, G.10
Bencardino, K.11
Cercek, A.12
Chen, C.T.13
Veronese, S.14
Zanon, C.15
Sartore-Bianchi, A.16
Gambacorta, M.17
Gallicchio, M.18
Vakiani, E.19
Boscaro, V.20
Medico, E.21
Weiser, M.22
Siena, S.23
Nicolantonio, F.D.I.24
Solit, D.25
Bardelli, A.26
more..
-
42
-
-
84896078397
-
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
-
PMID: 24553387
-
Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014; 6: 224ra26 [PMID: 24553387 DOI: 10.1126/scitranslmed.3007947]
-
(2014)
Sci Transl Med
, vol.6
, pp. 224ra26
-
-
Misale, S.1
Arena, S.2
Lamba, S.3
Siravegna, G.4
Lallo, A.5
Hobor, S.6
Russo, M.7
Buscarino, M.8
Lazzari, L.9
Sartore-Bianchi, A.10
Bencardino, K.11
Amatu, A.12
Lauricella, C.13
Valtorta, E.14
Siena, S.15
Nicolantonio, F.D.I.16
Bardelli, A.17
-
43
-
-
84879240684
-
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
-
PMID: 23404247
-
Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013; 133: 1259-1265 [PMID: 23404247 DOI: 10.1002/ijc.28106]
-
(2013)
Int J Cancer
, vol.133
, pp. 1259-1265
-
-
Valtorta, E.1
Misale, S.2
Sartore-Bianchi, A.3
Nagtegaal, I.D.4
Paraf, F.5
Lauricella, C.6
Dimartino, V.7
Hobor, S.8
Jacobs, B.9
Ercolani, C.10
Lamba, S.11
Scala, E.12
Veronese, S.13
Laurent-Puig, P.14
Siena, S.15
Tejpar, S.16
Mottolese, M.17
Punt, C.J.18
Gambacorta, M.19
Bardelli, A.20
Nicolantonio, F.D.I.21
more..
-
44
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
PMID: 20978259
-
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820 [PMID: 20978259 DOI: 10.1001/jama.2010.1535]
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Nicolantonio, F.D.I.3
Sartore-Bianchi, A.4
Tu, D.5
Siena, S.6
Lamba, S.7
Arena, S.8
Frattini, M.9
Piessevaux, H.10
Van Cutsem, E.11
O'Callaghan, C.J.12
Khambata-Ford, S.13
Zalcberg, J.R.14
Simes, J.15
Karapetis, C.S.16
Bardelli, A.17
Tejpar, S.18
-
45
-
-
84867117207
-
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
-
PMID: 22734028
-
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577 [PMID: 22734028 DOI: 10.1200/JCO.2012.42.2592]
-
(2012)
J Clin Oncol
, vol.30
, pp. 3570-3577
-
-
Tejpar, S.1
Celik, I.2
Schlichting, M.3
Sartorius, U.4
Bokemeyer, C.5
Van Cutsem, E.6
-
46
-
-
84955282009
-
Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
-
PMID: 26812186
-
Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer 2016; 55: 122-130 [PMID: 26812186 DOI: 10.1016/j.ejca.2015.11.025]
-
(2016)
Eur J Cancer
, vol.55
, pp. 122-130
-
-
Rowland, A.1
Dias, M.M.2
Wiese, M.D.3
Kichenadasse, G.4
McKinnon, R.A.5
Karapetis, C.S.6
Sorich, M.J.7
-
47
-
-
84949991071
-
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
-
PMID: 26371285
-
Schirripa M, Loupakis F, Lonardi S, Cremolini C, Bergamo F, Zagonel V, Falcone A. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol 2015; 26: 2503 [PMID: 26371285 DOI: 10.1093/annonc/mdv385]
-
(2015)
Ann Oncol
, vol.26
, pp. 2503
-
-
Schirripa, M.1
Loupakis, F.2
Lonardi, S.3
Cremolini, C.4
Bergamo, F.5
Zagonel, V.6
Falcone, A.7
-
48
-
-
84976351874
-
Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study
-
PMID: 27114605
-
Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. J Clin Oncol 2016; 34: 2258-2264 [PMID: 27114605 DOI: 10.1200/JCO.2015.65.6843]
-
(2016)
J Clin Oncol
, vol.34
, pp. 2258-2264
-
-
Segelov, E.1
Thavaneswaran, S.2
Waring, P.M.3
Desai, J.4
Robledo, K.P.5
Gebski, V.J.6
Elez, E.7
Nott, L.M.8
Karapetis, C.S.9
Lunke, S.10
Chantrill, L.A.11
Pavlakis, N.12
Khasraw, M.13
Underhill, C.14
Ciardiello, F.15
Jefford, M.16
Wasan, H.17
Haydon, A.18
Price, T.J.19
Van Hazel, G.20
Wilson, K.21
Simes, J.22
Shapiro, J.D.23
more..
-
49
-
-
84940474576
-
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
-
PMID: 25851630
-
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015; 26: 1710-1714 [PMID: 25851630 DOI: 10.1093/annonc/mdv176]
-
(2015)
Ann Oncol
, vol.26
, pp. 1710-1714
-
-
Normanno, N.1
Rachiglio, A.M.2
Lambiase, M.3
Martinelli, E.4
Fenizia, F.5
Esposito, C.6
Roma, C.7
Troiani, T.8
Rizzi, D.9
Tatangelo, F.10
Botti, G.11
Maiello, E.12
Colucci, G.13
Ciardiello, F.14
-
50
-
-
0029150669
-
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
-
PMID: 7585182
-
Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1: 792-797 [PMID: 7585182 DOI: 10.1038/nm0895-792]
-
(1995)
Nat Med
, vol.1
, pp. 792-797
-
-
Kohl, N.E.1
Omer, C.A.2
Conner, M.W.3
Anthony, N.J.4
Davide, J.P.5
DeSolms, S.J.6
Giuliani, E.A.7
Gomez, R.P.8
Graham, S.L.9
Hamilton, K.10
-
51
-
-
23844517889
-
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
-
PMID: 16133800
-
Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005; 23: 485-487 [PMID: 16133800 DOI: 10.1007/s10637-005-2908-y]
-
(2005)
Invest New Drugs
, vol.23
, pp. 485-487
-
-
Macdonald, J.S.1
McCoy, S.2
Whitehead, R.P.3
Iqbal, S.4
Wade, J.L.5
Giguere, J.K.6
Abbruzzese, J.L.7
-
52
-
-
84860540538
-
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
-
PMID: 22392911
-
Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012; 18: 2515-2525 [PMID: 22392911]
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2515-2525
-
-
Migliardi, G.1
Sassi, F.2
Torti, D.3
Galimi, F.4
Zanella, E.R.5
Buscarino, M.6
Ribero, D.7
Muratore, A.8
Massucco, P.9
Pisacane, A.10
Risio, M.11
Capussotti, L.12
Marsoni, S.13
Nicolantonio, F.D.I.14
Bardelli, A.15
Comoglio, P.M.16
Trusolino, L.17
Bertotti, A.18
-
53
-
-
84977625707
-
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
-
PMID: 27088596
-
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One 2016; 11: e0154007 [PMID: 27088596 DOI: 10.1371/journal.pone.0154007]
-
(2016)
PLoS One
, vol.11
, pp. e0154007
-
-
Costa-Cabral, S.1
Brough, R.2
Konde, A.3
Aarts, M.4
Campbell, J.5
Marinari, E.6
Riffell, J.7
Bardelli, A.8
Torrance, C.9
Lord, C.J.10
Ashworth, A.11
-
54
-
-
84888639050
-
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
-
PMID: 24256730
-
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-551 [PMID: 24256730 DOI: 10.1038/nature12796]
-
(2013)
Nature
, vol.503
, pp. 548-551
-
-
Ostrem, J.M.1
Peters, U.2
Sos, M.L.3
Wells, J.A.4
Shokat, K.M.5
-
55
-
-
84959020489
-
Sensitivity of KRASMutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
-
PMID: 26369631
-
Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS. Sensitivity of KRASMutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. Clin Cancer Res 2016; 22: 405-414 [PMID: 26369631]
-
(2016)
Clin Cancer Res
, vol.22
, pp. 405-414
-
-
Ziemke, E.K.1
Dosch, J.S.2
Maust, J.D.3
Shettigar, A.4
Sen, A.5
Welling, T.H.6
Hardiman, K.M.7
Sebolt-Leopold, J.S.8
-
56
-
-
84921415334
-
Recent therapeutic advances in the treatment of colorectal cancer
-
PMID: 25341011
-
Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med 2015; 66: 83-95 [PMID: 25341011 DOI: 10.1146/annurev-med-051513-102539]
-
(2015)
Annu Rev Med
, vol.66
, pp. 83-95
-
-
Ciombor, K.K.1
Wu, C.2
Goldberg, R.M.3
-
57
-
-
84979592925
-
-
ClinicalTrials.gov Identifier: NCT01274624
-
ClinicalTrials.gov Identifier: NCT01274624. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
58
-
-
18044387648
-
Raf kinase as a target for anticancer therapeutics
-
PMID: 15827342
-
Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-685 [PMID: 15827342 DOI: 10.1158/1535-7163.MCT-04-0297]
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 677-685
-
-
Sridhar, S.S.1
Hedley, D.2
Siu, L.L.3
-
59
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
PMID: 12068308
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954 [PMID: 12068308 DOI: 10.1038/nature00766]
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmieri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
60
-
-
0037194728
-
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
-
PMID: 12198537
-
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934 [PMID: 12198537 DOI: 10.1038/418934a]
-
(2002)
Nature
, vol.418
, pp. 934
-
-
Rajagopalan, H.1
Bardelli, A.2
Lengauer, C.3
Kinzler, K.W.4
Vogelstein, B.5
Velculescu, V.E.6
-
61
-
-
84862026304
-
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
-
PMID: 22446022
-
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475 [PMID: 22446022 DOI: 10.1016/j.ejca.2012.02.057]
-
(2012)
Eur J Cancer
, vol.48
, pp. 1466-1475
-
-
Bokemeyer, C.1
Van Cutsem, E.2
Rougier, P.3
Ciardiello, F.4
Heeger, S.5
Schlichting, M.6
Celik, I.7
Köhne, C.H.8
-
62
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
PMID: 19001320
-
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Nicolantonio, F.D.I.1
Martini, M.2
Molinari, F.3
Sartore-Bianchi, A.4
Arena, S.5
Saletti, P.6
De Dosso, S.7
Mazzucchelli, L.8
Frattini, M.9
Siena, S.10
Bardelli, A.11
-
63
-
-
73349094741
-
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
-
PMID: 19884556
-
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]
-
(2009)
J Clin Oncol
, vol.27
, pp. 5924-5930
-
-
Laurent-Puig, P.1
Cayre, A.2
Manceau, G.3
Buc, E.4
Bachet, J.B.5
Lecomte, T.6
Rougier, P.7
Lievre, A.8
Landi, B.9
Boige, V.10
Ducreux, M.11
Ychou, M.12
Bibeau, F.13
Bouché, O.14
Reid, J.15
Stone, S.16
Penault-Llorca, F.17
-
64
-
-
84879786289
-
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
-
PMID: 23725851
-
Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759 [PMID: 23725851 DOI: 10.1016/S1470-2045(13)70163-3]
-
(2013)
Lancet Oncol
, vol.14
, pp. 749-759
-
-
Seymour, M.T.1
Brown, S.R.2
Middleton, G.3
Maughan, T.4
Richman, S.5
Gwyther, S.6
Lowe, C.7
Seligmann, J.F.8
Wadsley, J.9
Maisey, N.10
Chau, I.11
Hill, M.12
Dawson, L.13
Falk, S.14
O'Callaghan, A.15
Benstead, K.16
Chambers, P.17
Oliver, A.18
Marshall, H.19
Napp, V.20
Quirke, P.21
more..
-
65
-
-
79956310674
-
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
-
PMID: 21228335
-
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]
-
(2011)
Ann Oncol
, vol.22
, pp. 1535-1546
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
De Braud, F.4
Schuch, G.5
Zubel, A.6
Celik, I.7
Schlichting, M.8
Koralewski, P.9
-
66
-
-
84925105975
-
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
-
PMID: 25673558
-
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594 [PMID: 25673558 DOI: 10.1016/j.ejca.2015.01.054]
-
(2015)
Eur J Cancer
, vol.51
, pp. 587-594
-
-
Pietrantonio, F.1
Petrelli, F.2
Coinu, A.3
Bartolomeo, M.D.I.4
Borgonovo, K.5
Maggi, C.6
Cabiddu, M.7
Iacovelli, R.8
Bossi, I.9
Lonati, V.10
Ghilardi, M.11
De Braud, F.12
Barni, S.13
-
67
-
-
84951810474
-
Phase II pilot study of vemurafenib in patients with metastatic braf-mutated colorectal cancer
-
PMID: 26460303
-
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 2015; 33: 4032-4038 [PMID: 26460303 DOI: 10.1200/JCO.2015.63.2497]
-
(2015)
J Clin Oncol
, vol.33
, pp. 4032-4038
-
-
Kopetz, S.1
Desai, J.2
Chan, E.3
Hecht, J.R.4
O'Dwyer, P.J.5
Maru, D.6
Morris, V.7
Janku, F.8
Dasari, A.9
Chung, W.10
Issa, J.P.11
Gibbs, P.12
James, B.13
Powis, G.14
Nolop, K.B.15
Bhattacharya, S.16
Saltz, L.17
-
68
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
PMID: 22281684
-
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103 [PMID: 22281684 DOI: 10.1038/nature10868]
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Nicolantonio, F.D.I.4
Salazar, R.5
Zecchin, D.6
Beijersbergen, R.L.7
Bardelli, A.8
Bernards, R.9
-
69
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
PMID: 23251002
-
Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-667 [PMID: 23251002 DOI: 10.1158/1078-0432.CCR-11-1446]
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
Tsao, C.C.4
Lemos, R.5
Dayyani, F.6
Gopal, Y.N.7
Jiang, Z.Q.8
Wistuba, I.I.9
Tang, X.M.10
Bornman, W.G.11
Bollag, G.12
Mills, G.B.13
Powis, G.14
Desai, J.15
Gallick, G.E.16
Davies, M.A.17
Kopetz, S.18
-
70
-
-
84951745408
-
Combined BRAF and MEK inhibition with dabrafenib and trametinib in braf v600-mutant colorectal cancer
-
PMID: 26392102
-
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 2015; 33: 4023-4031 [PMID: 26392102 DOI: 10.1200/JCO.2015.63.2471]
-
(2015)
J Clin Oncol
, vol.33
, pp. 4023-4031
-
-
Corcoran, R.B.1
Atreya, C.E.2
Falchook, G.S.3
Kwak, E.L.4
Ryan, D.P.5
Bendell, J.C.6
Hamid, O.7
Messersmith, W.A.8
Daud, A.9
Kurzrock, R.10
Pierobon, M.11
Sun, P.12
Cunningham, E.13
Little, S.14
Orford, K.15
Motwani, M.16
Bai, Y.17
Patel, K.18
Venook, A.P.19
Kopetz, S.20
more..
-
71
-
-
84927604543
-
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
-
PMID: 25589621
-
Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-1320 [PMID: 25589621 DOI: 10.1158/1078-0432.CCR-14-2779]
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1313-1320
-
-
Yaeger, R.1
Cercek, A.2
O'Reilly, E.M.3
Reidy, D.L.4
Kemeny, N.5
Wolinsky, T.6
Capanu, M.7
Gollub, M.J.8
Rosen, N.9
Berger, M.F.10
Lacouture, M.E.11
Vakiani, E.12
Saltz, L.B.13
-
72
-
-
0022789685
-
Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT)
-
PMID: 3549875
-
Kelway B, Simpson KH, Smith RJ, Halsall PJ. Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). Int Clin Psychopharmacol 1986; 1: 296-302 [PMID: 3549875 DOI: 10.1158/1078-0432]
-
(1986)
Int Clin Psychopharmacol
, vol.1
, pp. 296-302
-
-
Kelway, B.1
Simpson, K.H.2
Smith, R.J.3
Halsall, P.J.4
-
73
-
-
84979540512
-
-
ClinicalTrials.gov Identifier: NCT01750918; NCT01719380
-
ClinicalTrials.gov Identifier: NCT01750918; NCT01719380. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
74
-
-
84933040790
-
Clinical acquired resistance to raf inhibitor combinations in braf-mutant colorectal cancer through mapk pathway alterations
-
PMID: 25673644
-
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov 2015; 5: 358-367 [PMID: 25673644 DOI: 10.1158/2159-8290.CD-14-1518]
-
(2015)
Cancer Discov
, vol.5
, pp. 358-367
-
-
Ahronian, L.G.1
Sennott, E.M.2
Van Allen, E.M.3
Wagle, N.4
Kwak, E.L.5
Faris, J.E.6
Godfrey, J.T.7
Nishimura, K.8
Lynch, K.D.9
Mermel, C.H.10
Lockerman, E.L.11
Kalsy, A.12
Gurski, J.M.13
Bahl, S.14
Anderka, K.15
Green, L.M.16
Lennon, N.J.17
Huynh, T.G.18
Mino-Kenudson, M.19
Getz, G.20
Dias-Santagata, D.21
Iafrate, A.J.22
Engelman, J.A.23
Garraway, L.A.24
Corcoran, R.B.25
more..
-
75
-
-
85084273777
-
Subgroup analyses in RAS mutant, BRAF mutant and all-wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study
-
Cremolini C, Loupakis F, Lonardi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Valsuani C, Chiara S, Boni C, Marcucci L, Negri FV, Barone C, Vitello S, D'Amico M, Granetto C, Antoniotti C, Salvatore L, Fontanini G, Tomcikova D, Boni L, Falcone A. Subgroup analyses in RAS mutant, BRAF mutant and all-wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. Ann Oncol 2014; 25: ii107-ii108 [DOI: 10.1093/annonc/mdu193.7]
-
(2014)
Ann Oncol
, vol.25
, pp. ii107-ii108
-
-
Cremolini, C.1
Loupakis, F.2
Lonardi, S.3
Tomasello, G.4
Ronzoni, M.5
Zaniboni, A.6
Tonini, G.7
Valsuani, C.8
Chiara, S.9
Boni, C.10
Marcucci, L.11
Negri, F.V.12
Barone, C.13
Vitello, S.14
D'Amico, M.15
Granetto, C.16
Antoniotti, C.17
Salvatore, L.18
Fontanini, G.19
Tomcikova, D.20
Boni, L.21
Falcone, A.22
more..
-
76
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
-
PMID: 21163703
-
De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603 [PMID: 21163703 DOI: 10.1016/S1470-2045(10)70209-6]
-
(2011)
Lancet Oncol
, vol.12
, pp. 594-603
-
-
De Roock, W.1
De Vriendt, V.2
Normanno, N.3
Ciardiello, F.4
Tejpar, S.5
-
77
-
-
37249056471
-
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations
-
PMID: 18079394
-
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007; 318: 1744-1748 [PMID: 18079394 DOI: 10.1126/science.1150799]
-
(2007)
Science
, vol.318
, pp. 1744-1748
-
-
Huang, C.H.1
Mandelker, D.2
Schmidt-Kittler, O.3
Samuels, Y.4
Velculescu, V.E.5
Kinzler, K.W.6
Vogelstein, B.7
Gabelli, S.B.8
Amzel, L.M.9
-
78
-
-
33344462540
-
Mutation of the PIK3CA oncogene in human cancers
-
PMID: 16449998
-
Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455-459 [PMID: 16449998 DOI: 10.1038/sj.bjc.6602970]
-
(2006)
Br J Cancer
, vol.94
, pp. 455-459
-
-
Karakas, B.1
Bachman, K.E.2
Park, B.H.3
-
79
-
-
40949135397
-
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
-
PMID: 18339877
-
Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961 [PMID: 18339877 DOI: 10.1158/0008-5472. CAN-07-5659]
-
(2008)
Cancer Res
, vol.68
, pp. 1953-1961
-
-
Jhawer, M.1
Goel, S.2
Wilson, A.J.3
Montagna, C.4
Ling, Y.H.5
Byun, D.S.6
Nasser, S.7
Arango, D.8
Shin, J.9
Klampfer, L.10
Augenlicht, L.H.11
Perez-Soler, R.12
Mariadason, J.M.13
-
80
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
-
PMID: 19223544
-
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857 [PMID: 19223544 DOI: 10.1158/0008-5472.CAN-08-2466]
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
Veronese, S.4
Nichelatti, M.5
Artale, S.6
Nicolantonio, F.D.I.7
Saletti, P.8
De Dosso, S.9
Mazzucchelli, L.10
Frattini, M.11
Siena, S.12
Bardelli, A.13
-
81
-
-
84860634396
-
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
-
PMID: 22039088
-
Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23: 1518-1525 [PMID: 22039088 DOI: 10.1093/annonc/mdr464]
-
(2012)
Ann Oncol
, vol.23
, pp. 1518-1525
-
-
Mao, C.1
Yang, Z.Y.2
Hu, X.F.3
Chen, Q.4
Tang, J.L.5
-
82
-
-
84900569919
-
Antiepidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: A meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients
-
PMID: 24701207
-
Huang L, Liu Z, Deng D, Tan A, Liao M, Mo Z, Yang X. Antiepidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci 2014; 10: 1-9 [PMID: 24701207 DOI: 10.5114/aoms.2014.40728]
-
(2014)
Arch Med Sci
, vol.10
, pp. 1-9
-
-
Huang, L.1
Liu, Z.2
Deng, D.3
Tan, A.4
Liao, M.5
Mo, Z.6
Yang, X.7
-
83
-
-
84859865072
-
Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review
-
PMID: 22357840
-
Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-2268 [PMID: 22357840 DOI: 10.1158/1078-0432. CCR-11-2410]
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2257-2268
-
-
Liao, X.1
Morikawa, T.2
Lochhead, P.3
Imamura, Y.4
Kuchiba, A.5
Yamauchi, M.6
Nosho, K.7
Qian, Z.R.8
Nishihara, R.9
Meyerhardt, J.A.10
Fuchs, C.S.11
Ogino, S.12
-
84
-
-
63049111794
-
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
-
PMID: 19237633
-
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-1484 [PMID: 19237633 DOI: 10.1200/JCO.2008.18.6544]
-
(2009)
J Clin Oncol
, vol.27
, pp. 1477-1484
-
-
Ogino, S.1
Nosho, K.2
Kirkner, G.J.3
Shima, K.4
Irahara, N.5
Kure, S.6
Chan, A.T.7
Engelman, J.A.8
Kraft, P.9
Cantley, L.C.10
Giovannucci, E.L.11
Fuchs, C.S.12
-
85
-
-
4344602002
-
The biology and clinical relevance of the PTEN tumor suppressor pathway
-
PMID: 15254063
-
Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963 [PMID: 15254063 DOI: 10.1200/JCO.2004.02.141]
-
(2004)
J Clin Oncol
, vol.22
, pp. 2954-2963
-
-
Sansal, I.1
Sellers, W.R.2
-
86
-
-
35348908314
-
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
-
PMID: 17940504
-
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145 [PMID: 17940504 DOI: 10.1038/sj.bjc.6604009]
-
(2007)
Br J Cancer
, vol.97
, pp. 1139-1145
-
-
Frattini, M.1
Saletti, P.2
Romagnani, E.3
Martin, V.4
Molinari, F.5
Ghisletta, M.6
Camponovo, A.7
Etienne, L.L.8
Cavalli, F.9
Mazzucchelli, L.10
-
87
-
-
66849140563
-
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
-
PMID: 19398573
-
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-2629 [PMID: 19398573 DOI: 10.1200/JCO.2008.20.2796]
-
(2009)
J Clin Oncol
, vol.27
, pp. 2622-2629
-
-
Loupakis, F.1
Pollina, L.2
Stasi, I.3
Ruzzo, A.4
Scartozzi, M.5
Santini, D.6
Masi, G.7
Graziano, F.8
Cremolini, C.9
Rulli, E.10
Canestrari, E.11
Funel, N.12
Schiavon, G.13
Petrini, I.14
Magnani, M.15
Tonini, G.16
Campani, D.17
Floriani, I.18
Cascinu, S.19
Falcone, A.20
more..
-
88
-
-
84893461612
-
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17
-
PMID: 24218517
-
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O' Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-753 [PMID: 24218517 DOI: 10.1158/1078-0432.CCR-13-0606]
-
(2014)
Clin Cancer Res
, vol.20
, pp. 744-753
-
-
Karapetis, C.S.1
Jonker, D.2
Daneshmand, M.3
Hanson, J.E.4
O'Callaghan, C.J.5
Marginean, C.6
Zalcberg, J.R.7
Simes, J.8
Moore, M.J.9
Tebbutt, N.C.10
Price, T.J.11
Shapiro, J.D.12
Pavlakis, N.13
Gibbs, P.14
Van Hazel, G.A.15
Lee, U.16
Haq, R.17
Virk, S.18
Tu, D.19
Lorimer, I.A.20
more..
-
89
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network PMID: 22810696
-
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
90
-
-
77955288855
-
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
-
PMID: 20664172
-
Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-2866 [PMID: 20664172 DOI: 10.1172/JCI37539]
-
(2010)
J Clin Invest
, vol.120
, pp. 2858-2866
-
-
Nicolantonio, F.D.I.1
Arena, S.2
Tabernero, J.3
Grosso, S.4
Molinari, F.5
Macarulla, T.6
Russo, M.7
Cancelliere, C.8
Zecchin, D.9
Mazzucchelli, L.10
Sasazuki, T.11
Shirasawa, S.12
Geuna, M.13
Frattini, M.14
Baselga, J.15
Gallicchio, M.16
Biffo, S.17
Bardelli, A.18
-
91
-
-
84893249799
-
PI3K and cancer: Lessons, challenges and opportunities
-
PMID: 24481312
-
Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156 [PMID: 24481312 DOI: 10.1038/nrd4204]
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 140-156
-
-
Fruman, D.A.1
Rommel, C.2
-
92
-
-
84922092092
-
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
-
PMID: 25335932
-
Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, Infante JR, Barton J, Burris HA. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs 2015; 33: 187-193 [PMID: 25335932 DOI: 10.1007/s10637-014-0177-3]
-
(2015)
Invest New Drugs
, vol.33
, pp. 187-193
-
-
Bendell, J.C.1
Jones, S.F.2
Hart, L.3
Spigel, D.R.4
Lane, C.M.5
Earwood, C.6
Infante, J.R.7
Barton, J.8
Burris, H.A.9
-
93
-
-
84979542650
-
-
ClinicalTrials.gov Identifier: NCT01139138
-
ClinicalTrials.gov Identifier: NCT01139138
-
-
-
-
94
-
-
63349097231
-
Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
-
PMID: 19194827
-
Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009; 27: 273-285 [PMID: 19194827 DOI: 10.1080/0735790080231489 3]
-
(2009)
Cancer Invest
, vol.27
, pp. 273-285
-
-
Zhang, Y.J.1
Tian, X.Q.2
Sun, D.F.3
Zhao, S.L.4
Xiong, H.5
Fang, J.Y.6
-
95
-
-
84942279909
-
Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers
-
PMID: 26404261
-
Temraz S, Mukherji D, Shamseddine A. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci 2015; 16: 22976-22988 [PMID: 26404261 DOI: 10.3390/ijms160922976]
-
(2015)
Int J Mol Sci
, vol.16
, pp. 22976-22988
-
-
Temraz, S.1
Mukherji, D.2
Shamseddine, A.3
-
96
-
-
84979508345
-
-
ClinicalTrials.gov Identifier: NCT01363232; NCT01449058
-
ClinicalTrials.gov Identifier: NCT01363232; NCT01449058. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
97
-
-
84867817838
-
Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival
-
PMID: 23094721
-
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival. N Engl J Med 2012; 367: 1596-1606 [PMID: 23094721 DOI: 10.1056/NEJMoa1207756]
-
(2012)
N Engl J Med
, vol.367
, pp. 1596-1606
-
-
Liao, X.1
Lochhead, P.2
Nishihara, R.3
Morikawa, T.4
Kuchiba, A.5
Yamauchi, M.6
Imamura, Y.7
Qian, Z.R.8
Baba, Y.9
Shima, K.10
Sun, R.11
Nosho, K.12
Meyerhardt, J.A.13
Giovannucci, E.14
Fuchs, C.S.15
Chan, A.T.16
Ogino, S.17
-
98
-
-
0042307325
-
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
-
PMID: 12853564
-
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938 [PMID: 12853564 DOI: 10.1073/pnas.1537685100]
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 8933-8938
-
-
Holbro, T.1
Beerli, R.R.2
Maurer, F.3
Koziczak, M.4
Barbas, C.F.5
Hynes, N.E.6
-
99
-
-
80052591747
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
-
PMID: 21900593
-
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86 [PMID: 21900593 DOI: 10.1126/scitranslmed.3002442]
-
(2011)
Sci Transl Med
, vol.3
, pp. 99ra86
-
-
Yonesaka, K.1
Zejnullahu, K.2
Okamoto, I.3
Satoh, T.4
Cappuzzo, F.5
Souglakos, J.6
Ercan, D.7
Rogers, A.8
Roncalli, M.9
Takeda, M.10
Fujisaka, Y.11
Philips, J.12
Shimizu, T.13
Maenishi, O.14
Cho, Y.15
Sun, J.16
Destro, A.17
Taira, K.18
Takeda, K.19
Okabe, T.20
Swanson, J.21
Itoh, H.22
Takada, M.23
Lifshits, E.24
Okuno, K.25
Engelman, J.A.26
Shivdasani, R.A.27
Nishio, K.28
Fukuoka, M.29
Varella-Garcia, M.30
Nakagawa, K.31
Jänne, P.A.32
more..
-
100
-
-
84963976837
-
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial
-
PMID: 27108243
-
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746 [PMID: 27108243 DOI: 10.1016/S1470-2045(16)00150-9]
-
(2016)
Lancet Oncol
, vol.17
, pp. 738-746
-
-
Sartore-Bianchi, A.1
Trusolino, L.2
Martino, C.3
Bencardino, K.4
Lonardi, S.5
Bergamo, F.6
Zagonel, V.7
Leone, F.8
Depetris, I.9
Martinelli, E.10
Troiani, T.11
Ciardiello, F.12
Racca, P.13
Bertotti, A.14
Siravegna, G.15
Torri, V.16
Amatu, A.17
Ghezzi, S.18
Marrapese, G.19
Palmeri, L.20
Valtorta, E.21
Cassingena, A.22
Lauricella, C.23
Vanzulli, A.24
Regge, D.25
Veronese, S.26
Comoglio, P.M.27
Bardelli, A.28
Marsoni, S.29
Siena, S.30
more..
-
101
-
-
79952607191
-
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab
-
PMID: 21212430
-
Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011; 16: 53-60 [PMID: 21212430 DOI: 10.1634/theoncologist.2010-0119]
-
(2011)
Oncologist
, vol.16
, pp. 53-60
-
-
Scartozzi, M.1
Mandolesi, A.2
Giampieri, R.3
Bittoni, A.4
Pierantoni, C.5
Zaniboni, A.6
Galizia, E.7
Giustini, L.8
Silva, R.R.9
Bisonni, R.10
Berardi, R.11
Biscotti, T.12
Biagetti, S.13
Bearzi, I.14
Cascinu, S.15
-
102
-
-
84877839648
-
Oncogenic ERBB3 mutations in human cancers
-
PMID: 23680147
-
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013; 23: 603-617 [PMID: 23680147 DOI: 10.1016/j.ccr.2013.04.012]
-
(2013)
Cancer Cell
, vol.23
, pp. 603-617
-
-
Jaiswal, B.S.1
Kljavin, N.M.2
Stawiski, E.W.3
Chan, E.4
Parikh, C.5
Durinck, S.6
Chaudhuri, S.7
Pujara, K.8
Guillory, J.9
Edgar, K.A.10
Janakiraman, V.11
Scholz, R.P.12
Bowman, K.K.13
Lorenzo, M.14
Li, H.15
Wu, J.16
Yuan, W.17
Peters, B.A.18
Kan, Z.19
Stinson, J.20
Mak, M.21
Modrusan, Z.22
Eigenbrot, C.23
Firestein, R.24
Stern, H.M.25
Rajalingam, K.26
Schaefer, G.27
Merchant, M.A.28
Sliwkowski, M.X.29
De Sauvage, F.J.30
Seshagiri, S.31
more..
-
103
-
-
80054765331
-
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
-
PMID: 22014573
-
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20: 472-486 [PMID: 22014573 DOI: 10.1016/j.ccr.2011.09.003]
-
(2011)
Cancer Cell
, vol.20
, pp. 472-486
-
-
Schaefer, G.1
Haber, L.2
Crocker, L.M.3
Shia, S.4
Shao, L.5
Dowbenko, D.6
Totpal, K.7
Wong, A.8
Lee, C.V.9
Stawicki, S.10
Clark, R.11
Fields, C.12
Lewis Phillips, G.D.13
Prell, R.A.14
Danilenko, D.M.15
Franke, Y.16
Stephan, J.P.17
Hwang, J.18
Wu, Y.19
Bostrom, J.20
Sliwkowski, M.X.21
Fuh, G.22
Eigenbrot, C.23
more..
-
104
-
-
84874541055
-
A phase i study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts
-
Cervantes-Ruiperez A, Juric D, Hidalgo M, Messersmith WA, Blumenschein GR, Baselga J, Perez DR, Dienstmann R, Calles A, Jimeno A, Sanabria S, Littman C, Amler LC, Pirzkall A, Tabernero J. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts. J Clin Oncol 2012; 30 Suppl: abstract 2568
-
(2012)
J Clin Oncol
, vol.30
-
-
Cervantes-Ruiperez, A.1
Juric, D.2
Hidalgo, M.3
Messersmith, W.A.4
Blumenschein, G.R.5
Baselga, J.6
Perez, D.R.7
Dienstmann, R.8
Calles, A.9
Jimeno, A.10
Sanabria, S.11
Littman, C.12
Amler, L.C.13
Pirzkall, A.14
Tabernero, J.15
-
105
-
-
84979559086
-
-
Presented at AACR Annual Meeting, April 18-21, 2015, Philadelphia, PA
-
Presented at AACR Annual Meeting, April 18-21, 2015, Philadelphia, PA. Available from: URL: http://qfuse.com/client-downloads/AACR 2015-DARECK-poster-15Apr15.pdf
-
-
-
-
106
-
-
84951766343
-
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. Cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC)
-
Price TJ, Newhall J, Peeters M. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 Suppl 3: abstract 740
-
(2015)
J Clin Oncol
, vol.33
-
-
Price, T.J.1
Newhall, J.2
Peeters, M.3
-
107
-
-
76549085643
-
Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy
-
PMID: 20068188
-
Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588-597 [PMID: 20068188 DOI: 10.1158/0008-5472.CAN-09-1417]
-
(2010)
Cancer Res
, vol.70
, pp. 588-597
-
-
Pedersen, M.W.1
Jacobsen, H.J.2
Koefoed, K.3
Hey, A.4
Pyke, C.5
Haurum, J.S.6
Kragh, M.7
-
108
-
-
84932608425
-
Safety and activity of the first-in-class sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer
-
PMID: 25962717
-
Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov 2015; 5: 598-609 [PMID: 25962717 DOI: 10.1158/2159-8290.CD-14-1432]
-
(2015)
Cancer Discov
, vol.5
, pp. 598-609
-
-
Dienstmann, R.1
Patnaik, A.2
Garcia-Carbonero, R.3
Cervantes, A.4
Benavent, M.5
Roselló, S.6
Tops, B.B.7
Van Der Post, R.S.8
Argilés, G.9
Skartved, N.J.10
Hansen, U.H.11
Hald, R.12
Pedersen, M.W.13
Kragh, M.14
Horak, I.D.15
Braun, S.16
Van Cutsem, E.17
Tolcher, A.W.18
Tabernero, J.19
-
109
-
-
84939619336
-
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
-
PMID: 25911688
-
Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer Ther 2015; 14: 1625-1636 [PMID: 25911688 DOI: 10.1158/1535-7163.MCT-14-0772]
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 1625-1636
-
-
Kearns, J.D.1
Bukhalid, R.2
Sevecka, M.3
Tan, G.4
Gerami-Moayed, N.5
Werner, S.L.6
Kohli, N.7
Burenkova, O.8
Sloss, C.M.9
King, A.M.10
Fitzgerald, J.B.11
Nielsen, U.B.12
Wolf, B.B.13
-
110
-
-
44449151030
-
Drug development of MET inhibitors: Targeting oncogene addiction and expedience
-
PMID: 18511928
-
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516 [PMID: 18511928 DOI: 10.1038/nrd2530]
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
-
111
-
-
0028946604
-
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer
-
PMID: 9815967
-
Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1: 147-154 [PMID: 9815967]
-
(1995)
Clin Cancer Res
, vol.1
, pp. 147-154
-
-
Renzo, M.F.D.I.1
Olivero, M.2
Giacomini, A.3
Porte, H.4
Chastre, E.5
Mirossay, L.6
Nordlinger, B.7
Bretti, S.8
Bottardi, S.9
Giordano, S.10
-
112
-
-
84926361705
-
Prognostic value of c-Met in colorectal cancer: A meta-analysis
-
PMID: 25834339
-
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol 2015; 21: 3706-3710 [PMID: 25834339 DOI: 10.3748/wjg.v21.i12.3706]
-
(2015)
World J Gastroenterol
, vol.21
, pp. 3706-3710
-
-
Liu, Y.1
Yu, X.F.2
Zou, J.3
Luo, Z.H.4
-
113
-
-
46349092797
-
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
-
PMID: 18577988
-
Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99: 83-89 [PMID: 18577988 DOI: 10.1038/sj.bjc.6604439]
-
(2008)
Br J Cancer
, vol.99
, pp. 83-89
-
-
Cappuzzo, F.1
Varella-Garcia, M.2
Finocchiaro, G.3
Skokan, M.4
Gajapathy, S.5
Carnaghi, C.6
Rimassa, L.7
Rossi, E.8
Ligorio, C.9
Tommaso, L.D.I.10
Holmes, A.J.11
Toschi, L.12
Tallini, G.13
Destro, A.14
Roncalli, M.15
Santoro, A.16
Jänne, P.A.17
-
114
-
-
84890781022
-
Increased TGF as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells
-
PMID: 24122793
-
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-? as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013; 19: 6751-6765 [PMID: 24122793 DOI: 10.1158/1078-0432. CCR-13-0423]
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6751-6765
-
-
Troiani, T.1
Martinelli, E.2
Napolitano, S.3
Vitagliano, D.4
Ciuffreda, L.P.5
Costantino, S.6
Morgillo, F.7
Capasso, A.8
Sforza, V.9
Nappi, A.10
De Palma, R.11
D'Aiuto, E.12
Berrino, L.13
Bianco, R.14
Ciardiello, F.15
-
115
-
-
84905968151
-
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
-
PMID: 24919569
-
Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014; 20: 4240-4250 [PMID: 24919569 DOI: 10.1158/1078-0432.CCR-13-2752]
-
(2014)
Clin Cancer Res
, vol.20
, pp. 4240-4250
-
-
Van Cutsem, E.1
Eng, C.2
Nowara, E.3
Swieboda-Sadlej, A.4
Tebbutt, N.C.5
Mitchell, E.6
Davidenko, I.7
Stephenson, J.8
Elez, E.9
Prenen, H.10
Deng, H.11
Tang, R.12
McCaffery, I.13
Oliner, K.S.14
Chen, L.15
Gansert, J.16
Loh, E.17
Smethurst, D.18
Tabernero, J.19
-
116
-
-
84979615842
-
-
ClinicalTrials.gov Identifier: NCT02008383
-
ClinicalTrials.gov Identifier: NCT02008383. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
117
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
PMID: 19196673
-
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572 [PMID: 19196673 DOI: 10.1056/NEJMoa0808268]
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
Rodenburg, C.J.4
Creemers, G.J.5
Schrama, J.G.6
Erdkamp, F.L.7
Vos, A.H.8
Van Groeningen, C.J.9
Sinnige, H.A.10
Richel, D.J.11
Voest, E.E.12
Dijkstra, J.R.13
Vink-Börger, M.E.14
Antonini, N.F.15
Mol, L.16
Van Krieken, J.H.17
Dalesio, O.18
Punt, C.J.19
-
118
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
PMID: 19114685
-
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680 [PMID: 19114685 DOI: 10.1200/JCO.2008.19.8135]
-
(2009)
J Clin Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
Scroggin, C.4
Hagenstad, C.5
Spigel, D.6
Marshall, J.7
Cohn, A.8
McCollum, D.9
Stella, P.10
Deeter, R.11
Shahin, S.12
Amado, R.G.13
-
119
-
-
84883074556
-
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
-
PMID: 23690424
-
Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 2013; 31: 2477-2484 [PMID: 23690424 DOI: 10.1200/JCO.2012.46.0543]
-
(2013)
J Clin Oncol
, vol.31
, pp. 2477-2484
-
-
Siu, L.L.1
Shapiro, J.D.2
Jonker, D.J.3
Karapetis, C.S.4
Zalcberg, J.R.5
Simes, J.6
Couture, F.7
Moore, M.J.8
Price, T.J.9
Siddiqui, J.10
Nott, L.M.11
Charpentier, D.12
Liauw, W.13
Sawyer, M.B.14
Jefford, M.15
Magoski, N.M.16
Haydon, A.17
Walters, I.18
Ringash, J.19
Tu, D.20
O'Callaghan, C.J.21
more..
-
120
-
-
78751480476
-
MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
-
PMID: 21118963
-
Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011; 71: 445-453 [PMID: 21118963 DOI: 10.1158/0008-5472.CAN-10-3058]
-
(2011)
Cancer Res
, vol.71
, pp. 445-453
-
-
Yoon, J.1
Koo, K.H.2
Choi, K.Y.3
-
121
-
-
58349091262
-
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
-
PMID: 19147570
-
Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69: 565-572 [PMID: 19147570 DOI: 10.1158/0008-5472. CAN-08-3389]
-
(2009)
Cancer Res
, vol.69
, pp. 565-572
-
-
Mirzoeva, O.K.1
Das, D.2
Heiser, L.M.3
Bhattacharya, S.4
Siwak, D.5
Gendelman, R.6
Bayani, N.7
Wang, N.J.8
Neve, R.M.9
Guan, Y.10
Hu, Z.11
Knight, Z.12
Feiler, H.S.13
Gascard, P.14
Parvin, B.15
Spellman, P.T.16
Shokat, K.M.17
Wyrobek, A.J.18
Bissell, M.J.19
McCormick, F.20
Kuo, W.L.21
Mills, G.B.22
Gray, J.W.23
Korn, W.M.24
more..
-
122
-
-
66249116702
-
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
-
PMID: 19401449
-
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-4293 [PMID: 19401449 DOI: 10.1158/0008-5472. CAN-08-4765]
-
(2009)
Cancer Res
, vol.69
, pp. 4286-4293
-
-
Wee, S.1
Jagani, Z.2
Xiang, K.X.3
Loo, A.4
Dorsch, M.5
Yao, Y.M.6
Sellers, W.R.7
Lengauer, C.8
Stegmeier, F.9
-
123
-
-
84904388268
-
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition
-
PMID: 24812410
-
Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014; 20: 3775-3786 [PMID: 24812410 DOI: 10.1158/1078-0432. CCR-13-2181]
-
(2014)
Clin Cancer Res
, vol.20
, pp. 3775-3786
-
-
Troiani, T.1
Napolitano, S.2
Vitagliano, D.3
Morgillo, F.4
Capasso, A.5
Sforza, V.6
Nappi, A.7
Ciardiello, D.8
Ciardiello, F.9
Martinelli, E.10
-
124
-
-
84939617966
-
Primary and acquired resistance of colorectal cancer to anti-EGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab
-
PMID: 25838391
-
Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Clin Cancer Res 2015; 21: 2975-2983 [PMID: 25838391 DOI: 10.1158/1078-0432.CCR-15-0020]
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2975-2983
-
-
Napolitano, S.1
Martini, G.2
Rinaldi, B.3
Martinelli, E.4
Donniacuo, M.5
Berrino, L.6
Vitagliano, D.7
Morgillo, F.8
Barra, G.9
De Palma, R.10
Merolla, F.11
Ciardiello, F.12
Troiani, T.13
-
125
-
-
84856239290
-
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
-
PMID: 22210091
-
Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012; 17: 14 [PMID: 22210091 DOI: 10.1634/theoncologist.2011-0452]
-
(2012)
Oncologist
, vol.17
, pp. 14
-
-
Wadlow, R.C.1
Hezel, A.F.2
Abrams, T.A.3
Blaszkowsky, L.S.4
Fuchs, C.S.5
Kulke, M.H.6
Kwak, E.L.7
Meyerhardt, J.A.8
Ryan, D.P.9
Szymonifka, J.10
Wolpin, B.M.11
Zhu, A.X.12
Clark, J.W.13
-
126
-
-
78651081207
-
Safety and efficacy of panitumumab therapy after progression with cetuximab: Experience at two institutions
-
PMID: 21208847
-
Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9: 315-318 [PMID: 21208847 DOI: 10.3816/CCC.2010.n.046]
-
(2010)
Clin Colorectal Cancer
, vol.9
, pp. 315-318
-
-
Saif, M.W.1
Kaley, K.2
Chu, E.3
Copur, M.S.4
-
127
-
-
84979615821
-
-
ClinicalTrials.gov Identifier: NCT02296203; NCT02316496
-
ClinicalTrials.gov Identifier: NCT02296203; NCT02316496. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
128
-
-
84974792739
-
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
-
PMID: 27002107
-
Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27: 1055-1061 [PMID: 27002107 DOI: 10.1093/annonc/mdw136]
-
(2016)
Ann Oncol
, vol.27
, pp. 1055-1061
-
-
Ciardiello, F.1
Normanno, N.2
Martinelli, E.3
Troiani, T.4
Pisconti, S.5
Cardone, C.6
Nappi, A.7
Bordonaro, A.R.8
Rachiglio, M.9
Lambiase, M.10
Latiano, T.P.11
Modoni, G.12
Cordio, S.13
Giuliani, F.14
Biglietto, M.15
Montesarchio, V.16
Barone, C.17
Tonini, G.18
Cinieri, S.19
Febbraro, A.20
Rizzi, D.21
De Vita, F.22
Orditura, M.23
Colucci, G.24
Maiello, E.25
more..
-
129
-
-
80053644648
-
Phase i pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
-
PMID: 21900113
-
Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29: 3783-3790 [PMID: 21900113 DOI: 10.1200/JCO.2011.34.8888]
-
(2011)
J Clin Oncol
, vol.29
, pp. 3783-3790
-
-
Paz-Ares, L.G.1
Gomez-Roca, C.2
Delord, J.P.3
Cervantes, A.4
Markman, B.5
Corral, J.6
Soria, J.C.7
Bergé, Y.8
Roda, D.9
Russell-Yarde, F.10
Hollingsworth, S.11
Baselga, J.12
Umana, P.13
Manenti, L.14
Tabernero, J.15
-
130
-
-
84939611576
-
GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in secondline KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC)
-
Bridgewater JA, Cervantes A, Markman B, Siena S, Cubillo A, Carbonero RG, Sigal D, Aprile G, Cunningham D, Nadal C, Pericay C, Samuel LM, Hochhauser D, Perez-Fidalgo JA, Strickland A, Guizani C, Golding S, Valverde VL, Ott MG, Tabernero J. GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in secondline KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 Suppl: abstr 669
-
(2015)
J Clin Oncol
, vol.33
-
-
Bridgewater, J.A.1
Cervantes, A.2
Markman, B.3
Siena, S.4
Cubillo, A.5
Carbonero, R.G.6
Sigal, D.7
Aprile, G.8
Cunningham, D.9
Nadal, C.10
Pericay, C.11
Samuel, L.M.12
Hochhauser, D.13
Perez-Fidalgo, J.A.14
Strickland, A.15
Guizani, C.16
Golding, S.17
Valverde, V.L.18
Ott, M.G.19
Tabernero, J.20
more..
-
131
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
PMID: 26028255
-
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520 [PMID: 26028255 DOI: 10.1056/NEJMoa1500596]
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
Skora, A.D.7
Luber, B.S.8
Azad, N.S.9
Laheru, D.10
Biedrzycki, B.11
Donehower, R.C.12
Zaheer, A.13
Fisher, G.A.14
Crocenzi, T.S.15
Lee, J.J.16
Duffy, S.M.17
Goldberg, R.M.18
De La Chapelle, A.19
Koshiji, M.20
Bhaijee, F.21
Huebner, T.22
Hruban, R.H.23
Wood, L.D.24
Cuka, N.25
Pardoll, D.M.26
Papadopoulos, N.27
Kinzler, K.W.28
Zhou, S.29
Cornish, T.C.30
Taube, J.M.31
Anders, R.A.32
Eshleman, J.R.33
Vogelstein, B.34
Diaz, L.A.35
more..
-
132
-
-
84979636518
-
-
ClinicalTrials.gov Identifier: NCT02298946; NCT01375842; NCT02335918; NCT01633970; NCT01772004; NCT02227667
-
ClinicalTrials.gov Identifier: NCT02298946; NCT01375842; NCT02335918; NCT01633970; NCT01772004; NCT02227667. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
133
-
-
84925273291
-
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group n9831 adjuvant trastuzumab trial
-
PMID: 25605861
-
Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015; 33: 701-708 [PMID: 25605861]
-
(2015)
J Clin Oncol
, vol.33
, pp. 701-708
-
-
Perez, E.A.1
Thompson, E.A.2
Ballman, K.V.3
Anderson, S.K.4
Asmann, Y.W.5
Kalari, K.R.6
Eckel-Passow, J.E.7
Dueck, A.C.8
Tenner, K.S.9
Jen, J.10
Fan, J.B.11
Geiger, X.J.12
McCullough, A.E.13
Chen, B.14
Jenkins, R.B.15
Sledge, G.W.16
Winer, E.P.17
Gralow, J.R.18
Reinholz, M.M.19
-
134
-
-
84979634063
-
-
ClinicalTrials.gov Identifier: NCT01309126; NCT02318901
-
ClinicalTrials.gov Identifier: NCT01309126; NCT02318901. Available from: URL: https://clinicaltrials.gov/
-
-
-
-
135
-
-
84877579861
-
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
-
PMID: 23563269
-
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112 [PMID: 23563269 DOI: 10.1038/nature12065]
-
(2013)
Nature
, vol.497
, pp. 108-112
-
-
Murtaza, M.1
Dawson, S.J.2
Tsui, D.W.3
Gale, D.4
Forshew, T.5
Piskorz, A.M.6
Parkinson, C.7
Chin, S.F.8
Kingsbury, Z.9
Wong, A.S.10
Marass, F.11
Humphray, S.12
Hadfield, J.13
Bentley, D.14
Chin, T.M.15
Brenton, J.D.16
Caldas, C.17
Rosenfeld, N.18
|